Clinical trials: Muscle Spasm
Acute Musculoskeletal Spasm Due to Low Back Pain
A Clinical Trial to Study the Effects of a Fixed Dose Combination of Diclofenac and Eperisone Hydrochloride With Plain Eperisone Hydrochloride in Patients With Low Back Pain
The purpose of this study is to investigate the effects of a fixed dose combination of diclofenac and eperisone hydrochloride compared with plain eperisone hydrochloride in patients with low back pain.
- Trial name
- NCT01300312
- Testing
- Eperisone hydrochloride and Diclofenac sodium, Eperisone hydrochloride
- Where
- 4 sites in India
- Volunteers
- 239 people
- Sponsor
- Eisai Co., Ltd.
Blepharospasm, Hemifacial Spasm
Post Marketing Surveillance Study of Dysport
The purpose of this study is to provide further information regarding the risks and benefits of Dysport in marketed indications.
- Conditions
- Blepharospasm, Hemifacial Spasm, Cervical Dystonia, Spasmodic Torticollis
- Trial name
- NCT00210431
- Where
- 36 sites in France, Germany and 1 more
- Volunteers
- 783 people
- Sponsor
- Ipsen
Pain, Spasm
An Effectiveness and Safety Study of Cyclobenzaprine HCl Alone or in Combination With Ibuprofen for Acute Back or Neck Muscle Pain With Muscle Spasm
The purpose of this study is to evaluate the effectiveness and safety of cyclobenzaprine HCl 5 mg (muscle spasm medication) taken three times a day, alone or in combination with ibuprofen 400 mg or 800 mg (pain relief medication)…
- Trial name
- NCT00246389
- Testing
- cyclobenzaprine hydrochloride
- Volunteers
- 1,000 people
- Sponsor
- McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Intestinal Diseases
Efficacy of Buscopan® in Comparison With 654-II (Anisodamine) in Acute Gastric or Intestinal Pain
The aim of the study is to assess the efficacy of Buscopan® (hyoscine butylbromide) in comparison to 654-II (anisodamine)in acute gastric or intestinal spasm-like pain.
- Trial name
- NCT01929044
- Testing
- 654-II (anisodamine), Buscopan® (hyoscine butylbromide)
- Where
- 20 sites in China
- Volunteers
- 299 people
- Sponsor
- Boehringer Ingelheim
Asthma, Bronchospasm
Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006
The main objective is to evaluate the bronchodilatory efficacy, safety and pharmacokinetic profiles of A006 (Albuterol Dry Powder Inhaler (DPI)), in comparison with those of an active control, Proventil-HFA (Albuterol Metered…
- Conditions
- Asthma, Bronchospasm, Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT01189396
- Testing
- A006, Proventil-HFA
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Back Muscle Spasm, Back Pain
Efficacy and Safety of Tolperisone in Subjects With Pain Due to Acute Back Muscle Spasm
This is a double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of tolperisone (a non-opioid) or placebo administered in subjects with pain due to acute back muscle spasm.
- Conditions
- Back Muscle Spasm, Back Pain, Back Strain, Back Spasm Upper
- Trial name
- RESUME-1 (NCT04671082)
- Testing
- Tolperisone Hydrochloride
- Where
- 56 sites in United States
- Volunteers
- 1,004 people
- Sponsor
- Neurana Pharmaceuticals, Inc.
Asthma, Exercise-Induced
A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma
The purpose of this Phase III, multicentre, randomized, double-blind, single-dose, 2-period, crossover study is to assess the efficacy and safety of PT027 (budesonide/albuterol sulfate) metered-dose inhaler compared with placebo…
- Trial name
- BREATH (NCT06245551)
- Testing
- Budesonide/albuterol metered-dose inhaler 160/180 μg
- Where
- 6 sites in Russia
- Volunteers
- 64 people
- Sponsor
- AstraZeneca
Attention Deficit Hyperactivity Disorder
Concordance of the Quotient Attention Deficit Hyperactivity Disorder (ADHD) System Report With Teacher and Parent Assessments for Symptoms of ADHD
To demonstrate concordance between the Quotient ADHD System Report and standard DSM-IV based parent and teacher reported rating/assessment scales, currently the accepted method of symptom measurement for subjects diagnosed with…
- Trial name
- NCT01118650
- Sponsor
- BioBehavioral Diagnostics Company
Attention Deficit Hyperactivity Disorder (ADHD)
Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years
The purpose of this study is to evaluate the efficacy and safety of SHP465 at 6.25 mg in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6-12 years.
- Trial name
- NCT03325881
- Testing
- SHP465
- Where
- 41 sites in United States
- Volunteers
- 89 people
- Sponsor
- Shire
CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure
A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.
This is a Phase 3 Study to examine the efficacy and safety of ZX008 in children and adults with cyclin-dependent kinase like-5 (CDKL5) deficiency disorder (CDD).
- Conditions
- CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures
- Trial name
- GEMZ (NCT05064878)
- Testing
- Fenfluramine
- Where
- 46 sites in United States, Austria and 12 more
- Volunteers
- 87 people
- Sponsor
- Zogenix, Inc.
Attention Deficit Hyperactivity Disorder (ADHD)
Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
The purpose of the study is to evaluate the long-term safety and tolerability of SHP465 at 6.25 milligram (mg) in children aged 4 to 12 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT03325894
- Testing
- SHP465
- Where
- 48 sites in United States
- Volunteers
- 141 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder, ADHD
Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting
The time course of response following one dose of a new methylphenidate hydrochloride extended release capsule is studied in children 6-12 years in a simulated laboratory classroom setting.
- Trial name
- NCT01269463
- Testing
- Methylphenidate Hydrochloride Extended Release Capsule
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
Pulmonary Disease, Chronic Obstructive, Bronchospasm
Prophylactic Efficacy of Relenza Against Influenza A and B
In response to the European regulatory authorities, GSK is conducting a post-marketing observational study to assess the efficacy of Relenza when used as prophylaxis against influenza. SPECIFIC AIMS 1.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Bronchospasm, Influenza, Human, Asthma
- Trial name
- NCT01156701
- Testing
- Receiving a prescription of Relenza for prophylaxis, No prophylaxis with Relenza
- Volunteers
- 171,705 people
- Sponsor
- GlaxoSmithKline
Bronchospasm
A First Time In Human Study To Assess The Compound GSK615915
GSK615915A is being developed as a novel surfactant for use in the formulation of GSK's future generation of Metered Dose Inhalers (MDIs).
- Trial name
- NCT00400660
- Testing
- GSK615915A
- Where
- United Kingdom
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Abdominal Pain
Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Tablets for the Treatment of Occasional or Recurrent Episodes of Gastric or Intestinal Spasm-like Pain or Discomfort
In contrast with Hyoscine Butylbromide Capsule 10mg, Study is to evaluate the efficacy and safety of Hyoscine Butylbromide tablets 10 mg (20mg, 3 times daily, orally) over a period of 3 days for the treatment of occasional or…
- Trial name
- NCT02242305
- Testing
- Hyoscine Butylbromide - Tablet, Hyoscine Butylbromide - Capsule
- Volunteers
- 302 people
- Sponsor
- Boehringer Ingelheim
Back Pain, Acute Pain
Tolperisone in Acute Muscle Spasm of the Back
This is a double-blind, randomized, placebo-controlled, parallel group study of the efficacy and safety of tolperisone (a non-opioid) or placebo administered as multiple doses three times a day (TID) in approximately 400 male and…
- Conditions
- Back Pain, Acute Pain, Back Spasm Upper Back, Back Strain
- Trial name
- STAR (NCT03802565)
- Testing
- Tolperisone
- Where
- 43 sites in United States
- Volunteers
- 415 people
- Sponsor
- Neurana Pharmaceuticals, Inc.
Impacted Third Molar, Postoperative Pain
Natural Enzyme Mouthwash After Third Molar Surgery
This clinical study investigates whether a natural enzyme-containing mouthwash (ORAL7®) can improve healing, pain and mouth opening after the surgical removal of impacted lower wisdom teeth (mandibular third molars), compared to…
- Conditions
- Impacted Third Molar, Postoperative Pain, Trismus, Wound Healing
- Trial name
- NCT07627945
- Testing
- ORAL7® Mouthwash, 0.2% Chlorhexidine Gluconate Mouthwash
- Where
- Malaysia
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- MBD MARKETING SDN. BHD.
Urinary Catheters, Bladder Pain and Discomfort
FLUME Catheter Comfort Study
The Flume catheter is a commercially available (FDA 510(k) cleared) urethral catheter with an innovative catheter design. The traditional Foley catheter design includes a protruding tip with drainage holes.
- Conditions
- Urinary Catheters, Bladder Pain and Discomfort, Urine Leakage, Bladder Spasm
- Trial name
- NCT05785858
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- The Flume Catheter Company Ltd
Neck Pain, Back Pain
Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin
The purpose of this study was to assess the effect of cyclobenzaprine hydrochloride (HCl) extended release (CER) 15 mg capsule once daily in participants with muscle spasms associated with acute painful musculoskeletal conditions.
- Conditions
- Neck Pain, Back Pain, Spasm
- Trial name
- NCT02814565
- Testing
- Cyclobenzaprine HCl
- Where
- 10 sites in Russia
- Volunteers
- 180 people
- Sponsor
- Takeda
Pertussis, Whooping Cough
Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Years
This study will evaluate the safety and efficacy of 9 different vaccines containing aP (acellular pertussis) and TdaP (acellular pertussis, tetanus and diphtheria) in healthy subjects 18 to 40 years of age.
- Conditions
- Pertussis, Whooping Cough, Tetanus, Lockjaw
- Trial name
- NCT01529645
- Testing
- Acellular pertussis vaccine, Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed), Licensed TdaP booster vaccine
- Where
- Belgium
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines